Topical Amino Acid Composition for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dermatological conditions such as atopic dermatitis rely heavily on topical corticosteroids and immunomodulators, which have adverse side effects and safety concerns, necessitating a non-corticosteroidal and non-immunomodulator alternative for long-lasting symptom management.
Innovation Solution
A topical composition comprising L-leucine, L-isoleucine, L-valine, and their derivatives, combined with enzyme activators like caprylic acid, hexanoic acid, and thiamin diphosphate, is administered to improve symptoms like erythema, pruritus, exudation, and lichenification, potentially offering a steroid-free and safer management option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids are used to treat dermatological conditions, then inflammation and itching are reduced, but adverse side effects occur with long-term use
Solution Approach 1:
The patent extracts and eliminates corticosteroids and immunomodulators from the treatment regimen, replacing them with a composition of amino acids (L-leucine, L-isoleucine, L-valine) and enzyme activators (caprylic acid, hexanoic acid, thiamin diphosphate). This extraction removes the harmful elements while maintaining therapeutic effectiveness through alternative mechanisms that support skin barrier function and reduce inflammation without steroid-related side effects.
Solution Approach 2:
The patent employs naturally occurring, biodegradable amino acids and enzyme activators that are metabolized by the body rather than accumulating like synthetic corticosteroids. These components are processed through normal metabolic pathways, providing a safer long-term treatment option that avoids the cumulative toxicity and side effects associated with prolonged corticosteroid use.
2Reliability
If topical immunomodulators are used for dermatological condition management, then symptoms are controlled, but safety concerns arise due to potential malignancy development
Solution Approach 1:
The patent removes immunomodulators like tacrolimus and pimecrolimus from the treatment approach, replacing them with amino acids and enzyme activators that work through metabolic and barrier-repair mechanisms rather than immunosuppression. This extraction eliminates the black box warning associated with immunomodulator use while maintaining symptom control through alternative pathways.
Solution Approach 2:
The patent uses naturally occurring amino acids and enzyme activators that are rapidly metabolized and eliminated through normal bodily functions, avoiding the long-term accumulation and potential carcinogenic effects associated with immunomodulator use. These components provide temporary, controlled action without the safety concerns of malignancy development.
3Duration of action of moving object
If conventional treatments are used for dermatological conditions, then symptoms are ameliorated, but the treatment does not provide long-lasting relief after discontinuation
Solution Approach 1:
The patent employs amino acids and enzyme activators that work preliminarily to restore and strengthen the skin barrier function before symptoms fully manifest. By addressing the underlying barrier defect through metabolic support and enzyme activation, the treatment creates a resilient skin barrier that maintains improvement even after discontinuation, providing long-lasting relief rather than temporary symptom suppression.
Solution Approach 2:
The patent enables the skin to serve itself by providing building blocks (amino acids) and activation agents (enzyme activators) that allow the body's own metabolic pathways to repair and maintain the skin barrier. This self-service approach creates sustainable, long-term improvement as the skin's inherent repair mechanisms are enhanced rather than externally suppressed.
Data Source
AI summary
Provided herein are methods of improving one or more symptoms of a dermatological condition in a patient. The methods comprise topically administering a topical composition to the patient comprising a branched chain amino acid, and an enzyme activator. Also provided are kits comprising the topical composition and optionally a topical steroid.